Pap Smear Research Study
Evaluation of the Role of Human Papillomavirus Testing and p16 Expression in the Management of Patients Undergoing Cervical Cancer Screening
1 other identifier
interventional
1,712
1 country
1
Brief Summary
The principal hypothesis of this study is that HPV testing and/or p16 testing, either alone or in combination or associated with a Pap smear, will demonstrate greater specificity for clinically significant precancerous disease than will a Pap smear alone and that these tests will be of comparable or superior sensitivity than the Pap smear.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2006
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2008
CompletedFirst Submitted
Initial submission to the registry
August 28, 2008
CompletedFirst Posted
Study publicly available on registry
August 29, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2011
CompletedFebruary 22, 2018
February 1, 2018
1.7 years
August 28, 2008
February 20, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To provide cervical cancer screening (Pap smear, HPV test and/or p16 tests) to determine whether further intervention (colposcopy) is required
1st visit, 12 months, 18 months follow up
Study Arms (1)
1
OTHERHealthy patients screened for cervical cancer
Interventions
If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
Eligibility Criteria
You may qualify if:
- years and older
- Ability to speak and clearly understand English
- Female patients
You may not qualify if:
- No previous history of Cervical Cancer Treatment(LEEP,Laser,Cone etc.)
- Women who have had Pap smears within the previous 10 months
- Women under the age of 18.
- Women who are pregnant.
- Inability to give informed consent in English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Health Network - Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joan K Murphy, MD,FRCSC
University Health Network, Toronto
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 28, 2008
First Posted
August 29, 2008
Study Start
December 1, 2006
Primary Completion
August 1, 2008
Study Completion
January 1, 2011
Last Updated
February 22, 2018
Record last verified: 2018-02